TABLE 3.
Exosome-mediated therapies in thyroid cancer.
| Approaches | Effect | Reference | |
|---|---|---|---|
| Therapeutic target | Exosomal miR-152 | Inhibit TC cell proliferation, migration and invasion by binding with DPP-4 | Tang et al. (2020) |
| Silencing miRNA423-5p in exosomes | Inhibit PTC cell migration and invasion | Ye et al. (2019) | |
| Drug delivery | Exosomes loaded SCD-1 siRNA | Inhibit ATC cellular proliferation and promote cellular apoptosis | Wang M. H. et al. (2022) |
| Combining irradiation and chemotherapy by means of iRGD-targeted exosomes | Delivering 131I and doxorubicin to ATC cells, leading to significant tumor growth inhibition in mouse model | Wang C. et al. (2022) | |
| Exosomes from the cultured ATC cells | Exosomes were targeted into ATC cells | Gangadaran et al. (2018) | |
| Radiotherapy Immunotherapy | Exosomes used as vehicles for TKIs | Re-establishing radioiodine-sensitivity | Rajendran et al. (2021) |
| NK-cell-derived exosomes treated with IL-15 | Showed higher cytolytic activity toward human thyroid cancer cells | Zhu et al. (2019) | |
| NK-cell-derived exosomes | Exert strong killing effects to ATC cells | Zhu et al. (2018) |
DPP4, Dipeptidyl dipeptidase 4; TKIs, Tyrosine kinase inhibitors; IL-15, Interleukin-15; NK, Nature killing cell.